Autoplaque vs Viz AAA
AI Verdict
Choose Autoplaque if…
Choose Autoplaque if your primary need is detailed, quantitative analysis of coronary plaques and luminal stenoses from CT angiography images. This tool is ideal for comprehensive risk stratification of patients with coronary artery disease, enabling precise treatment guidance and long-term management planning based on in-depth plaque characterization.
View Autoplaque →Choose Viz AAA if…
Choose Viz AAA if your priority is the rapid detection and immediate triage of suspected Abdominal Aortic Aneurysm (AAA) from CT angiography scans. This solution is best suited for emergency medicine and vascular surgery departments requiring accelerated diagnosis, real-time alerts, and seamless care team coordination to optimize time-sensitive interventions for AAA patients.
View Viz AAA →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Autoplaque | Viz AAA |
|---|---|---|
| Pricing | Unknown | Enterprise (hospital/health system) |
| Deployment | Workstation-based post-processing application, runs on Windows or Mac OS. | Cloud-based, integrates with PACS and EHR systems. |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Viz AAAViz AAA (Tool B) offers cloud-based deployment, real-time alerts, and mobile access to imaging and patient information, suggesting a highly integrated and accessible user experience within existing hospital workflows. Autoplaque (Tool A) is workstation-based, which may limit its flexibility and integration compared to a cloud solution with mobile capabilities.
Clinical Value
Viz AAABoth tools are FDA-cleared and provide significant clinical value in their respective domains. However, Viz AAA has recent clinical validation studies demonstrating high sensitivity and specificity for AAA detection in real-world data, emphasizing its impact on accelerating diagnosis and care coordination for a time-sensitive condition. Autoplaque also has clinical validation, focusing on quantitative plaque analysis for risk prediction.
Pricing & Value
Viz AAAViz AAA (Tool B) offers a transparent subscription model with annual fees based on algorithms and population served, providing clarity on its pricing structure. Autoplaque (Tool A) has not disclosed its pricing, making it difficult to assess its value proposition.
Enterprise Readiness
Viz AAAViz AAA (Tool B) demonstrates strong enterprise readiness with its cloud-based deployment, explicit HIPAA compliance, and availability of a Business Associate Agreement (BAA). Its features like integration into existing workflows, real-time alerts, and a HIPAA-compliant communication platform are crucial for large-scale hospital adoption. Autoplaque (Tool A) is workstation-based and does not specify HIPAA compliance or BAA availability in the provided facts, which are key considerations for enterprise deployment.
Innovation
Viz AAAWhile both are innovative and FDA-cleared, Viz AAA (Tool B) stands out with its 'first FDA-cleared' claim for AAA detection and its comprehensive approach to intelligent care coordination, including automated triage, real-time alerts, and a communication platform. This extends innovation beyond just image analysis to workflow and multidisciplinary team collaboration. Autoplaque (Tool A) focuses on advanced quantitative plaque analysis, which is innovative in its depth, but Viz AAA's broader impact on the care pathway for an acute condition gives it an edge in overall innovation.
Support & Docs
Viz AAAViz.ai provides a Knowledge Base with articles on troubleshooting, app instructions, and contacting support, indicating a structured approach to user assistance. While Cedars-Sinai AIM provides user manuals for Autoplaque, the publicly available information on dedicated support channels is less explicit than Viz.ai's comprehensive knowledge base.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Autoplaque | Viz AAA |
|---|---|---|
| Name | Autoplaque | Viz AAA |
| Company | Cedars-Sinai Medical Center: AIM | Viz.ai |
| Primary AI Focus | Quantitative analysis of coronary plaques and luminal stenoses from CT angiography images | Detection and triage of suspected Abdominal Aortic Aneurysm (AAA) from CT angiography scans |
| Key Detection/Analysis | AI-powered quantitative analysis of atherosclerotic plaque, detection and characterization of coronary artery plaque, measurement of luminal stenoses, automated vessel, plaque, and lumen segmentation | AI-powered automatic detection of suspected AAA from CTA scans, automated triage and prioritization of cases, real-time alerts to care teams |
| Specialties | Cardiology, Radiology | Emergency Medicine, Radiology, Vascular Surgery |
Videos
Demos, reviews, and walkthroughs featuring Autoplaque and Viz AAA.